Recent News on

NET Alliance Issues New E-Book on Neuroendocrine Cancer

May 12, 2014

NETrospectives, a new e-book produced by The NET Alliance, is "a journey through the past and a vision for the future of neuroendocrine cancer." The e-book presents patients, patient advocates, and physicians talking about the diagnoses of these rare diseases, imaging techniques and treatment options, raising the standard of care, and connecting with others in the carcinoid/neuroendocrine tumor (NET) community. Read more

Luncheon with the Experts in New York City

April 13, 2014

Join carcinoid and neuroendocrine tumor patients on Sunday, May 4, 2014 for a unique opportunity to have lunch with three medical experts.  Share your experiences with others who have similar concerns and hear from the physicians on issues ranging from NET cancer treatments and surgery to carcinoid heart disease to follow-up testing and new developments.  Read more

AJCC Names Chair of Neuroendocrine Tumors Expert Panel

April 7, 2014

Eugene A. Woltering, MD, The James D. Rives Professor of Surgery and Neuroscience and Director of Surgical Research at LSU Health Sciences Center in Kenner, Louisiana, has been selected to serve as Chair of the Neuroendocrine Tumors Expert Panel for the American Joint Committee on Cancer’s (AJCC) Cancer Staging System, 8th Edition. Read more

BerriHealth Supports NET Cancer Research

March 25, 2014

BerriHealth, a leader in providing high-quality black raspberry powder for clinical trials and directly to consumers online, has donated a portion of their 2013 sales to New Orleans Louisiana Neuroendocrine Tumor Specialists (NOLANETS), led by Dr. Eugene Woltering. In 2014, BerriHealth is working to expand their support for cancer research. Read more

NIH Clinical Trial

March 7, 2014

Learn more about a unique opportunity for carcinoid and NET cancer patients to have a state-of-the-art scan: the Gallium-68 (GA-68) DOTATATE PET/CT scan. Click Here

First Global NET Cancer Patient Survey

March 3, 2014

Please help the Carcinoid Cancer Foundation in collaboration with the Caring for Carcinoid Foundation – both members of the International Neuroendocrine Cancer Alliance (INCA) -- increase awareness and education about NET worldwide by completing the first ever global survey of carcinoid and neuroendocrine tumor (NET) cancer patients! Read more

The online survey closed on May 31, 2014.  Thank you to the nearly 2,000 NET patients around the world who completed the survey!!!

Now Online -- New Jersey Carcinoid Cancer NETwork Conference Videos

January 20, 2014

Videos from the New Jersey Carcinoid Cancer NETwork Conference, held on November 2, 2013, are now available online.  The guest speakers for the conference were carcinoid/neuroendocrine tumor specialists Dr. Richard R.P. Warner, Dr. Eric H. Liu, and Dr. Yi-Zarn Wang and endocrinologist Dr. Justina DeitzClick here to read more and see the videos.

Annual Appeal 2013

December 3, 2013

Please read our Annual Appeal letter from Jeffrey M. Gregory as he talks about how the Carcinoid Cancer Foundation made a significant difference for him and his wife, Jackie.  Read more about Jackie’s Journey with carcinoid.  Donations to the Annual Appeal can be made online or by mail.

You can make a real difference in the lives of those facing carcinoid cancer and other neuroendocrine tumors by supporting The Carcinoid Cancer Foundation (CCF). Your contributions help fund our work of increasing awareness and educating the general public and healthcare professionals about carcinoid and related neuroendocrine cancers; providing support for patients and their loved ones; and serving as advocates for the carcinoid/NET (neuroendocrine tumor community).  These programs lead towards our ultimate goals of early detection, a possible cure, and improving the quality of life for cancer survivors and their families.

Every donation counts -- help bring us one step closer to our goals.

Endurance Competitive Rider and Goblet Cell Carcinoid Cancer Survivor Takes on New International Challenge

November 26, 2013

Battling goblet cell carcinoid cancer has not deterred Monica Grundmann from pursuing her dream as an endurance rider with her Morab stallion, Excalibur Legend.  Next month Monica will represent Eastern Canada in the North American Team Challenge 160-km, a 24-hour Endurance Race in Florida, competing against Western Canada, the U.S. and Mexico. ““I have always and will continue to live each day as if it is my last - saying and doing the maximum,” says Monica. “Obviously my personal goals regarding my beloved stallion, his competitions and his legacy, are paramount for me. Together, he and I have achieved much more than I ever could have dreamed and I am extremely grateful for being blessed to have him.” Read more about Monica’s amazing accomplishments and her journey with a rare cancer.

FDA Grants Orphan Drug Designation to Gallium-68 DOTATOC for Neuroendocrine Tumor Management

November 22, 2013

BREAKING NEWS – The radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Read more from the Society of Nuclear Medicine and Molecular Imaging and from Josh Mailman, chairman of the Society’s Patient Advocacy Advisory Board and president of the NorCal CarciNET support group in California. From the FDA, here’s information about how drugs are designated as an orphan product, read more.